Bangalore, India -- (SBWIRE) -- 12/02/2016 -- Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Report forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hofmann-La Roche
- Eli Lilly
- AstraZeneca
- Pfizer
- Celgene

Other prominent vendors
- Abbvie
- Aetna
- Agennix
- Allergan
- Amgen
- ARIAD Pharmaceuticals
- Astellas Pharma
- Betta Pharmaceuticals
- BeyondSpring Pharmaceuticals
- BioNumerik Pharmaceuticals
- Boehringer Ingelheim
- Boston Biomedical
- Bristol-Myers Squibb
- Celldex
- CTI BioPharma
- Eisai
- GlaxoSmithKline
- GTx
- Helsinn
- Hutchison Medipharma
- Ionis Pharmaceuticals
- Kadmon Corporation
- MabVax
- Merck
- Novartis
- NovaRx Corporation
- OncoGeneX
- Ono Pharmaceutical
- OSE Immunotherapeutics
- OSI Pharmaceuticals
- Peregrine
- PharmaMar
- Pierre Fabre
- Qiagen
- Recombio
- Samsung Bioepis
- Sanofi
- SFJ Pharmaceuticals
- Spectrum Pharmaceuticals
- Sumitomo Dainippon Pharma
- Synta
- Takeda Pharmaceuticals
- Teva Pharmaceutical
- Xcovery

Market driver
- Growing demand for targeted therapies
- For a full, detailed list, view our report

Market challenge
- Growing popularity of alternative therapeutics
- For a full, detailed list, view our report

Market trend
- Emergence of nanomedicine platform for the treatment of lung cancer
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 101 pages "Global Lung Cancer Therapeutics Market 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Disease overview, Pipeline analysis, Market landscape, Market segmentation by disease type, Market segmentation by type of molecule, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-lung-cancer-therapeutics-market-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.